Search Results

There are 8036 results for: content related to: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

  1. You have full text access to this Open Access content
    Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors

    Cancer Science

    Volume 103, Issue 11, November 2012, Pages: 1946–1954, Kunihiko Minakata, Fumiyuki Takahashi, Takeshi Nara, Muneaki Hashimoto, Ken Tajima, Akiko Murakami, Fariz Nurwidya, Suzu Yae, Fumiaki Koizumi, Hiroyuki Moriyama, Kuniaki Seyama, Kazuto Nishio and Kazuhisa Takahashi

    Article first published online : 14 SEP 2012, DOI: 10.1111/j.1349-7006.2012.02408.x

  2. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Article first published online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  3. You have free access to this content
    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01)

    Cancer

    Volume 118, Issue 24, 15 December 2012, Pages: 6234–6242, Jong-Mu Sun, Ki Hyeong Lee, Sang-we Kim, Dae Ho Lee, Young Joo Min, Hwan Jung Yun, Hoon Kyo Kim, Hong Suk Song, Yeul Hong Kim, Bong-Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Jae Won Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn and for the Korean Cancer Study Group (KCSG)

    Article first published online : 6 JUN 2012, DOI: 10.1002/cncr.27630

  4. You have free access to this content
    Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response

    International Journal of Cancer

    Volume 120, Issue 7, 1 April 2007, Pages: 1579–1590, Jean-Gabriel Judde, Magali Rebucci, Nicolas Vogt, Patricia de Cremoux, Alain Livartowski, Alain Chapelier, Carine Tran-Perennou, Karine Boye, Rémy Defrance, Marie-France Poupon and Rui-Alberto Bras-Gonçalves

    Article first published online : 4 JAN 2007, DOI: 10.1002/ijc.22364

  5. You have full text access to this Open Access content
    Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports

    Cancer Science

    Volume 102, Issue 5, May 2011, Pages: 1032–1037, Takehito Shukuya, Toshiaki Takahashi, Rieko Kaira, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Kazuhisa Takahashi and Nobuyuki Yamamoto

    Article first published online : 28 FEB 2011, DOI: 10.1111/j.1349-7006.2011.01887.x

  6. You have free access to this content
    Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin

    Asia-Pacific Journal of Clinical Oncology

    Volume 3, Issue 2, June 2007, Pages: 66–78, Alison ARMOUR

    Article first published online : 4 JUN 2007, DOI: 10.1111/j.1743-7563.2007.00090.x

  7. You have full text access to this OnlineOpen article
    Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

    Journal of Cellular and Molecular Medicine

    Volume 18, Issue 8, August 2014, Pages: 1519–1539, Luis Paz-Ares, Denis Soulières, Joachim Moecks, Ilze Bara, Tony Mok and Barbara Klughammer

    Article first published online : 6 AUG 2014, DOI: 10.1111/jcmm.12278

  8. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 3, September 2012, Pages: 232–243, Yi-Long WU, Da-Tong CHU, Baohui HAN, Xuyi LIU, Li ZHANG, Caicum ZHOU, Meilin LIAO, Tony MOK, Haiyi JIANG, Emma DUFFIELD and Masahiro FUKUOKA

    Article first published online : 23 APR 2012, DOI: 10.1111/j.1743-7563.2012.01518.x

  9. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 8, August 2012, Pages: 2763–2776, Brian J. Trummer, Vandana Iyer, Sathy V. Balu-Iyer, Robert O'Connor and Robert M. Straubinger

    Article first published online : 11 MAY 2012, DOI: 10.1002/jps.23180

  10. You have full text access to this Open Access content
    Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study

    Thoracic Cancer

    Volume 3, Issue 1, February 2012, Pages: 27–33, Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou and You Lu

    Article first published online : 5 FEB 2012, DOI: 10.1111/j.1759-7714.2011.00087.x

  11. You have free access to this content
    Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

    International Journal of Cancer

    Volume 123, Issue 12, 15 December 2008, Pages: 2939–2949, Tiziana Servidei, Anna Riccardi, Simona Mozzetti, Cristiano Ferlini and Riccardo Riccardi

    Article first published online : 19 SEP 2008, DOI: 10.1002/ijc.23902

  12. You have full text access to this Open Access content
    Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation

    Cancer Science

    Volume 99, Issue 8, August 2008, Pages: 1679–1684, Akira Inoue, Hong Xin, Takuji Suzuki, Masahiko Kanehira, Yoshio Kuroki, Tatsuro Fukuhara, Toshiaki Kikuchi, Makoto Maemondo, Toshihiro Nukiwa and Yasuo Saijo

    Article first published online : 14 AUG 2008, DOI: 10.1111/j.1349-7006.2008.00857.x

  13. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck

    Head & Neck

    Volume 34, Issue 11, November 2012, Pages: 1517–1523, Cristina P. Rodriguez, David J. Adelstein, Lisa A. Rybicki, Jerrold P. Saxton, Robert R. Lorenz, Benjamin G. Wood, Joseph Scharpf and Denise I. Ives

    Article first published online : 16 DEC 2011, DOI: 10.1002/hed.21971

  14. You have full text access to this Open Access content
    Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter

    Cancer Science

    Volume 99, Issue 9, September 2008, Pages: 1747–1753, Kadoaki Ohashi, Kammei Rai, Yoshiro Fujiwara, Masahiro Osawa, Seiki Hirano, Katsuyoshi Takata, Eisaku Kondo, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto and Katsuyuki Kiura

    Article first published online : 28 JUN 2008, DOI: 10.1111/j.1349-7006.2008.00875.x

  15. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 3, September 2012, Pages: 267–274, Chong-Kin LIAM, Muventhiran RUTHRANESAN, Chee-Hong LEE, Yong-Kek PANG, Keong-Tiong CHUA and Boon-Khaw LIM

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1743-7563.2011.01509.x

  16. You have full text access to this Open Access content
    Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation

    Cancer Science

    Volume 98, Issue 3, March 2007, Pages: 357–363, Akiko Uchida, Seiki Hirano, Hiroyuki Kitao, Atsuko Ogino, Kanmei Rai, Shinichi Toyooka, Nagio Takigawa, Masahiro Tabata, Minoru Takata, Katsuyuki Kiura and Mitsune Tanimoto

    Article first published online : 1 FEB 2007, DOI: 10.1111/j.1349-7006.2007.00387.x

  17. You have free access to this content
    The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

    International Journal of Cancer

    Volume 120, Issue 6, 15 March 2007, Pages: 1239–1247, Shuji Ichihara, Shinichi Toyooka, Yoshiro Fujiwara, Katsuyuki Hotta, Hisayuki Shigematsu, Masaki Tokumo, Junichi Soh, Hiroaki Asano, Kouichi Ichimura, Keisuke Aoe, Motoi Aoe, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date and Nobuyoshi Shimizu

    Article first published online : 27 DEC 2006, DOI: 10.1002/ijc.22513

  18. You have free access to this content
    Targeted therapy: An evolving world of lung cancer

    Respirology

    Volume 16, Issue 1, January 2011, Pages: 13–21, Kwok-Chi LAM and Tony S. MOK

    Article first published online : 16 AUG 2010, DOI: 10.1111/j.1440-1843.2010.01821.x

  19. You have full text access to this Open Access content
    Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer

    Thoracic Cancer

    Volume 5, Issue 2, March 2014, Pages: 149–154, Jianliang Yang, Yuankai Shi, Xiangru Zhang, Jianping Xu, Bin Wang, Xuezhi Hao, Junling Li and Wang Yan

    Article first published online : 3 MAR 2014, DOI: 10.1111/1759-7714.12074

  20. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma

    The Journal of Pathology

    Volume 225, Issue 1, September 2011, Pages: 83–95, Amandine Hurbin, Marie Wislez, Benoît Busser, Martine Antoine, Corine Tenaud, Nathalie Rabbe, Sandrine Dufort, Florence de Fraipont, Denis Moro-Sibilot, Jacques Cadranel, Jean-Luc Coll and Elisabeth Brambilla

    Article first published online : 19 MAY 2011, DOI: 10.1002/path.2897